Clinical trials: Metabolic Evaluation
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of…
- Trial name
- NCT07893093
- Testing
- ASC36 Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Malabsorption
Use of a Peptide-based Formula in an Adult Population
The study is designed to observe the use of a peptide-based oral nutrition supplement in adults with chronic malabsorption or maldigestion who require supplemental nutrition as assessed by a clinician.
- Trial name
- NCT02750787
- Testing
- Nutritional Study Product
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Abbott Nutrition
Metabolism and Nutrition Disorder, Obesity
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers
This trial is conducted in Europe. The aim of this clinical trial is to investigate the effect of liraglutide on gastric emptying, energy expenditure and appetite, and to evaluate liraglutide pharmacokinetics in non-diabetic…
- Trial name
- NCT00978393
- Testing
- liraglutide
- Where
- Netherlands
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
The primary objective of this study is to evaluate the effectiveness of HRS9531 compared to placebo in controlling blood glucose levels after 36 weeks of treatment
- Trial name
- NCT06650007
- Testing
- HRS9531 Injection
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus
This study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of JNJ-38431055 in volunteers with type 2 diabetes mellitus.
- Trial name
- NCT00871507
- Testing
- JNJ-38431055 Dose 1, Sitagliptin 100 mg, JNJ-38431055 Dose 2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight and Obese Volunteers.
Efficacy and Safety of a Fungal Chitosan on the Body Weight Reduction in Overweight and Obesity Volunteers
The prevalence of overweight and obesity is getting more and more important in developed as well as in emerging countries. It can be defined according to the degree of fat storage by measurement of fat mass.
- Trial name
- NCT02246699
- Testing
- KiOnutrime®-Cs
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Kitozyme
Hypercholesterolemia
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy (LMT)…
- Trial name
- NCT02289963
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 27 sites in South Korea, Taiwan
- Volunteers
- 199 people
- Sponsor
- Sanofi
Frontotemporal Dementia
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
- Trial name
- NCT04374136
- Testing
- Part 1 Blinded - AL001, Part 2 (OLE Treatment) - AL001
- Where
- 44 sites in United States, Argentina and 14 more
- Volunteers
- 119 people
- Sponsor
- Alector Inc.
Atherosclerosis
A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
The primary objective of this study is to examine the effects of SB-480848 on plasma lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a 4-week treatment with SB-480848.
- Trial name
- NCT00734032
- Testing
- SB480848 40mg EC Tablet, SB480848 80mg EC Tablet, SB480848 160mg EC Tablet
- Where
- 7 sites in Japan
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
Objective Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
- Trial name
- NCT05113693
- Testing
- CKD-393, CKD-501, D759, H053
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00449930
- Testing
- sitagliptin phosphate, Comparator: metformin hydrochloride
- Volunteers
- 1,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
[14C] Mass Balance Clinical Trial of Azvudine in Healthy Male Subjects
Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance.
- Trial name
- NCT07002281
- Testing
- [14C]Azvudine suspension
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Obesity
A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.
- Trial name
- NCT06259981
- Testing
- GLY-200
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Glyscend, Inc.
Diabetic Nephropathy, Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
The purpose of this study is to evaluate the effect of treatment with CCX140-B on urinary albumin excretion in subjects with type 2 diabetes mellitus and albuminuria, as well as to study the safety and efficacy of the medication…
- Trial name
- NCT01440257
- Testing
- CCX140-B
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
Denosumab China Phase III Study
This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.
- Trial name
- NCT02014467
- Testing
- Denosumab, Elemental Calcium, Vitamin D
- Where
- 8 sites in China
- Volunteers
- 486 people
- Sponsor
- GlaxoSmithKline
Obesity or Overweight
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male…
- Trial name
- VISTA (NCT06579092)
- Testing
- AZD5004
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the effectiveness and safety of IBI362 in patients with type 2 diabetes (T2D) with poor glycemia control only through diet…
- Trial name
- NCT05628311
- Testing
- IBI362
- Where
- China
- Volunteers
- 319 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes Mellitus
An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)
To determine the pharmacokinetic properties, safety and tolerability of single/multiple oral administration of Gemigliptin and Food effect in healthy Chinese subjects.
- Trial name
- NCT03864432
- Testing
- Gemigliptin 25mg, Gemigliptin 50mg, Gemigliptin 100mg
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Type 1 Diabetes Mellitus
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes mellitus. There are 2 parts to this study.
- Trial name
- NCT03465878
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Canada, Germany
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Diabetes
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes
This trial is conducted in China. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of mutiple-dose GZR4 in subjects with type 2 diabetes
- Trial name
- NCT06553248
- Testing
- GZR4, Insulin Degludec
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.